Author: Ravi Shankar

• In the phase III IMAgINATION study, sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential
• Sefaxersen inhibits complement factor B production at its primary source in the liver, thus blocking a key driver of IgAN-related kidney damage¹
• IgAN is a progressive kidney disease that is typically diagnosed in young adults and up to 50% of people progress to kidney failure within 20 years, requiring dialysis or transplantation^2-4
• Interim data will be presented at an upcoming medical meeting and shared with health authorities

Basel, 23 September 2026 – Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today positive prespecified interim results from the ongoing phase III IMAgINATION study evaluating investigational sefaxersen in adults with primary IgA nephropathy (IgAN). The study met its primary endpoint with sefaxersen achieving statistically significant and clinically meaningful improvements in proteinuria reduction, compared to placebo at 37 weeks, as measured by 24-hour urine protein-to-creatinine ratio (UPCR). Proteinuria is a key indicator of kidney damage and a reduction in UPCR is strongly associated with the preservation of long-term kidney function.^5,6 Sefaxersen is a once-monthly subcutaneous injection designed to enable self-administration for people with IgAN. The safety and tolerability profile of sefaxersen was consistent with previously reported data, with no new safety signals identified.

“These interim phase III results show the clinical potential of sefaxersen to modify a key surrogate endpoint of kidney function in people with IgA nephropathy’’ said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “Sefaxersen may therefore offer a new treatment option to help slow disease progression and potentially reduce the long-term need for dialysis or kidney transplantation.”

“For patients and families navigating IgAN, the prospect of kidney failure, dialysis, or transplantation creates overwhelming uncertainty,” said Bonnie Schneider, Director and Co-Founder of the IgA Nephropathy Foundation. “As someone who has advocated for this community for over two decades, positive results from the IMAgINATION study give us hope that emerging therapies could help preserve kidney function and transform the treatment landscape.”

The IMAgINATION study will continue as a blinded study to evaluate the change in kidney function over two years, as measured by estimated glomerular filtration rate (eGFR) at week 105. Interim analysis data will be presented at an upcoming medical congress and shared with health authorities, with the goal of bringing this treatment to patients as soon as possible.

IgAN, also known as Berger’s disease, is a chronic and progressive autoimmune disease that leads to end-stage kidney disease in up to 50% of patients within 20 years of diagnosis.^3,4 Typically diagnosed before the age of 40 years, it affects at least 25 adults per million worldwide each year.^7,8 It is the most common form of primary glomerulonephritis (inflammation of the tiny filters, glomeruli, in the kidneys) and is a major cause of chronic kidney disease as well as kidney failure.⁷

About sefaxersen
Sefaxersen, an investigational highly specific liver-directed antisense oligonucleotide that inhibits factor B production, is the first mRNA-targeted therapy for IgA nephropathy (IgAN).¹ Serum complement factor B levels are elevated in people with IgAN. When we reduce these levels, it in turn reduces the level of protein in urine, which is a key indicator of improved kidney function.^9,10

Sefaxersen is designed to provide sustained control of the alternative complement pathway, an important pathway in IgAN, enabling once-monthly subcutaneous dosing and is intended for self-administration in people with IgAN.¹¹ In phase I and II trials, sefaxersen was shown to be generally well tolerated in healthy volunteers and people with IgAN who were at high risk of progression, and reduced proteinuria and plasma complement factor B.^1,12

Roche licensed sefaxersen from Ionis for the treatment of complement mediated diseases.

About the IMAgINATION study
IMAgINATION [NCT05797610] is a phase III, multicentre, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneous sefaxersen, an investigational antisense inhibitor of complement factor B, in patients with primary IgA nephropathy at high risk of progression.^11,13 The study enrolled 459 people, who are randomised 1:1 to receive sefaxersen or placebo for 105 weeks.^11,13 Participants may switch to open-label treatment after week 105 at the investigator’s discretion or after the common-close timepoint, whichever occurs first.^11,13 The primary endpoint of the study is the change from baseline in the urine protein-to-creatinine ratio at 37 weeks.^11,13

About primary immunoglobulin A nephropathy (IgAN)
IgAN, also known as Berger’s disease, is a serious, chronic and progressive autoimmune kidney disease affecting at least 25 adults per million worldwide each year and is typically diagnosed before the age of 40 years.^4,7,8 In IgAN, immune complexes deposit in the kidneys, which activates the complement system’s alternative pathway, leading to inflammation and subsequent kidney damage.¹⁴ It is the most common form of primary glomerulonephritis (inflammation of kidney glomeruli) and remains a leading cause of kidney failure, with up to 50% of patients experiencing end-stage kidney disease within 20 years of diagnosis.^3,7 Many current therapies aim to reduce protein levels in the urine and control blood pressure to slow progression of the disease.¹⁵

Updated KDIGO 2025 guidelines* highlight the need to address both the underlying immune-mediated causes of IgAN and the downstream consequences of kidney damage.¹⁶ While new therapies have expanded treatment options, important unmet needs remain, including improved long-term preservation of kidney function and more targeted approaches that address key drivers of disease progression.^15,16

About Roche in Immunology
For over two decades, Roche has advanced immune system research, creating groundbreaking targeted treatments that have transformed care for people with blood disorders, neurological conditions and autoimmune diseases. With a development pipeline exploring more than 20 medical approaches, we are targeting widespread, complex conditions like chronic lung disease (COPD) and inflammatory bowel disease (IBD), alongside lupus, autoimmune kidney diseases and severe skin conditions (atopic dermatitis). Our ultimate goal is to lessen the burden of chronic immune disorders on patients, healthcare systems, and society.

About Roche
Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions.

Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.

Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

*KDIGO guidelines serve as the foundational framework for healthcare organisations, policymakers, and clinicians worldwide to standardise kidney disease diagnosis, staging, and treatment.

References
[1]  Barbour SJ, et al. A single-arm phase 2 trial of an investigational RNA therapeutic to complement factor B sefaxersen for treatment of IgA nephropathy. Kidney Int. 2026;109:592-601.
[2] Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1–S276.
[3]  Caster DJ, et al. Clinicopathological characteristics of adult IgA nephropathy in the United States. Kidney Int Rep. 2023;8:1792-1800
[4] Cleveland Clinic. IgA Nephropathy [Internet; cited 2026 Sep 16]. Available from: https://my.clevelandclinic.org/health/diseases/5990-iga-nephropathy  
[5] Longhitano E, et al. Proteinuria and Progression of Renal Damage: The Main Pathogenetic Mechanisms and Pharmacological Approach. Medicina (Kaunas). 2024 Nov 6;60(11):1821.
[6] Qin X, et al. Association Between Urinary Protein-to-Creatinine Ratio and Chronic Kidney Disease Progression: A Secondary Analysis of a Prospective Cohort Study. Front. Med. 2022; 9:854300.
[7] Pitcher D, et al. Long-term outcomes in IgA nephropathy. Clin J Am Soc Nephrol. 2023;18:727-738.
[8] McGrogan A, Franssen CF and de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant 2011; 26: 414-430.
[9] Chiu YL, et al. Alternative complement pathway is activated and associated with galactose-deficient IgA. Front Immunol 2021; 12: 638309.
[10] Marques F, et al. Impact of early proteinuria reduction in glomerular disease and decline of kidney function: a retrospective cohort. J Clin Med. 2022;11(19):5968.
[11] Barratt J, et al. IMAGINATION: a global phase 3 trial of RO7434656, an antisense oligonucleotide inhibitor of complement factor B, in IgA nephropathy. Kidney Int Rep. 2024;9 Suppl. WCN24-912.
[12] McCaleb ML, et al. Inhibiting the alternative pathway of complement by reducing systemic complement factor B: Randomized, double-blind, placebo-controlled phase 1 studies with Sefaxersen. Immunobiology. 2025 Mar;230(2):152876.
[13] ClinicalTrials.gov. A Study to Evaluate RO7434656 in Participants With Immunoglobulin A Nephropathy (IgAN) (IMAGINATION) (NCT05797610) [Internet; cited 2026 Sep 16]. Available from: https://clinicaltrials.gov/study/NCT05797610  
[14] Wu MY, et al. The emerging role of pathogenesis of IgA nephropathy. J Clin Med. 2018;7:225.
[15] Floege J, et al. Current treatment of IgA nephropathy. Semin Immunopathol. 2021;43:717-728.
[16] Kidney Disease: Improving Global Outcomes (KDIGO) IgAN and IgAV Work Group. KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). Kidney Int. 2025;108(4S):S1–S71

Roche Global Media Relations
Phone: +41 61 688 88 88 / e-mail: media.relations@roche.com

Tristan Schmitz Phone: +41 79 529 70 35	Lorena Corfas Phone: +41 79 568 24 95
Simon Goldsborough Phone: +44 797 32 72 915	Karsten Kleine Phone: +41 79 461 86 83
Kirti Pandey Phone: +41 79 398 38 53	Yvette Petillon Phone: +41 79 961 92 50
Irène Stephan Phone:  +41 79 377 83 75	Albert Thottiyil Phone: +41 79 775 66 12

Roche Investor Relations

Dr Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com	Dr Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com
Dr Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com

Investor Relations North America

Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com

Attachment

• Media Investor Release sefaxersen English

Roche announced today that the Board of Directors of Roche Holding Ltd has approved to propose Dr. Christophe Weber, former CEO of Takeda Pharmaceuticals, for election to the Board of Directors at Roche’s Annual General Meeting on March 9, 2027.

Roche Chairman Severin Schwan: “I am pleased that we have been able to propose Christophe Weber for election to the Board of Directors. Christophe’s intimate knowledge of the healthcare industry and his broad leadership experience will further strengthen our Board.”

About Roche
Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions.

Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceuticals Divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.

Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

 

Roche Global Media Relations
Phone: +41 61 688 88 88 / e-mail: media.relations@roche.com

Tristan Schmitz Phone: +41 79 529 70 35	Lorena Corfas Phone: +41 79 568 24 95
Simon Goldsborough Phone: +44 797 32 72 915	Karsten Kleine Phone: +41 79 461 86 83
Kirti Pandey Phone: +41 79 398 38 53	Yvette Petillon Phone: +41 79 961 92 50
Irène Stephan Phone:  +41 79 377 83 75	Albert Thottiyil Phone: +41 79 775 66 12

Attachment

• Media Release Change in BoD English

Press Release
23 September 2026

First-half 2026 results:
AFL Group reports solid results and achieves strategic milestones in the development of its refinancing tools

As of 30 June 2026, in a complex geopolitical and financial environment, AFL Group reports solid results and displays a robust financial structure: 

• Net interest margin increases to €15.6m (vs. €15.2m in the first half of 2025), supported by the continued growth in outstanding loans.
• Net banking income amounts to €15.1m, close to the €15.4m recorded in the first half of 2025, a historically strong period in terms of earnings.
• Gross operating income reaches €4.2m.
• The Group launched major initiatives to diversify and optimise its funding sources, generating nearly €1m in associated non-recurring costs.
• One capital increase enabled 29 new shareholder local governments to join the AFL Group, bringing the total number of shareholders to 1,300.
• Balance-sheet strength is confirmed by robust liquidity and capital ratios, with regulatory capital increasing by more than €20m over the half-year.

Key figures as of 30/06/2026 (IFRS) (vs. 30 June 2025)

	AFL Group1 (consolidated – IFRS)	AFL2 (consolidated – IFRS)
Net banking income	€15.1m (vs. €15.4m)	€15.0m (vs. €15.3m)
Operating expenses	€10.9m (vs. €9.1m)	€10.9m (vs. €9.0m)
Gross operating income	€4.2m (vs. €6.3m)	€4.2m (vs. €6.3m)
Pre-tax income	€3.9m (vs. €6.3m)	€3.9m (vs. €6.3m)
Net profit	€2.8m (vs. €4.7m)	€2.8m (vs. €4.6m)
Cost/income ratio3	81.7% (vs. 66.4%)	81.7% (vs. 66.3%)

“The first half of 2026 opens a new chapter in AFL Group’s development. As a new electoral cycle begins for municipalities and intermunicipal bodies, we remain fully committed to our mission of financing local public investment.
 The Group delivers solid results in the first half-year period, demonstrating the resilience of its business model. The continued growth of our business activity, the strengthening of our own funds and the quality of our financial structure allow us to approach the next stages of our development with confidence.” explains Yves Millardet, Chairman of AFL’s Executive Board.

Positive results supported by continued growth in outstanding loans, despite non-recurring items  

Core business revenues continue to grow, driven by the steady increase in loans granted to shareholder local governments. Gross operating income is affected during the half-year period by non-recurring expenses, primarily related to the ongoing acquisition project of GE SCF S.C.A.

Adjusted for these non-recurring items, gross operating income amounts to €5.1m.

As of 30 June 2026, outstanding signed loans continue their steady growth and reach €10.4bn.

Cost of risk remains inherently limited

AFL’s cost of risk remains inherently limited, reflecting its public development credit institution model, its prudent risk management framework, the very strong credit quality of French local governments⁴ and the quality of the assets held within its liquidity reserve.

As of 30 June 2026, AFL records a €234k charge relating to IFRS 9 expected credit loss provisions. Total provisions represent approximately 0.014% of assets.

These provisions primarily reflect changes in the assumptions used to build macroeconomic scenarios across asset classes, together with balance-sheet growth.

Strengthened prudential own funds

During the first half of 2026, AFL’s prudential own funds increase by more than €20m, mainly as a result of earnings retention from the previous financial year and capital contributions from shareholder local governments.

This momentum illustrates the strength of AFL’s model: business growth and the commitment of its shareholder local governments jointly contribute to strengthening its development and enhancing its capacity to support local public investment.

This translates into high capital ratios as of 30 June 2026:

• AFL Group CET1 ratio: 55.67% (vs. 59.45% as of 31 December 2025) / AFL: 54.15% (vs. 57.78%)
• AFL Group Tier 1 ratio: 57.37% (vs. 61.33%) / AFL: 63.61% (vs. 68.71%)
• AFL Group banking leverage ratio: 2.45% (vs. 2.32%) / AFL: 2.71% (vs. 2.59%)
• AFL Group leverage ratio for public development credit institutions: 11.37% (vs. 11.18%) / AFL: 12.67% (vs. 12.58%).

High liquidity levels

In line with its prudent management principles, AFL maintains very strong liquidity levels as of 30 June 2026:

• AFL’s Liquidity Coverage Ratio (LCR) stands at 250% (vs. 485% as of 31 December 2025 and a regulatory minimum of 100%)
• AFL’s internal 12-month liquidity ratio (NCRR) stands at 161% as of 30 June 2026 (vs. 101% as of 31 December 2025), corresponding to a €2.4bn liquidity reserve, enabling AFL to meet all its funding needs for more than one year without recourse to the capital markets.

The strength of AFL’s financial structure is recognised by the rating agencies, assigning it ratings equivalent to those of the French sovereign.

AFL Ratings

	Fitch Ratings	Standard & Poor’s
Long-term rating	A+	A+
Outlook	Stable	Stable
Short-term rating	F1+	A-1

Significant events during the first half of 2026

Launch of major strategic initiatives to diversify and optimise AFL’s funding costs for the benefit of local governments

Since 2024, AFL’s funding cost in the bond markets, as more broadly that of French public sector issuers, has increased significantly following the downgrade of the French sovereign rating.

Against this backdrop, AFL is pursuing two major strategic initiatives aimed at strengthening its refinancing capabilities over the long term. The first involves securing access to the covered bond market through the proposed acquisition of GE SCF S.C.A., a French specialised credit institution issuer of covered bond (“société de credit foncier”), subject to the required regulatory approvals. The second focuses on obtaining a 0% prudential risk weighting for AFL’s senior debt securities.

These initiatives share a common objective: to diversify funding sources, enhance the resilience of AFL’s business model and preserve the best possible financing conditions for local and regional governments.

Enhanced presence in the capital markets

During the first half of 2026, AFL has raised €1bn to an average spread of 14.6 basis points over the OAT curve, despite a more challenging market environment.

AFL completed its first Australian domestic bond issuance in May 2026, for an amount equivalent to €366m. This transaction marks an important milestone in AFL’s refinancing strategy and supports the diversification of its investor base while contributing to the optimization of funding costs.

Through a new €500m benchmark bond issue launched in May 2026, AFL completed its euro yield curve with a new September 2033 reference maturity. The transaction received exceptionally strong investor demand, generating the largest order book in AFL’s history at €3.7bn.

AFL continues its commitment to sustainable finance

As part of its annual funding programme and its ongoing efforts to continuously enhance its sustainable finance framework, AFL published on 29 June 2026 an updated version of its Sustainability Bond Framework.

The revised framework is aligned with international market standards, including the Green Bond Principles, Social Bond Principles and Sustainability Bond Guidelines published by the International Capital Market Association (ICMA).

The framework also received an independent external assessment through a Second Party Opinion issued by EthiFinance:

• Framework: View the ESG issuance framework
• SPO EthiFinance: View the Second Party Opinion

Subsequent events

• On 22 September 2026, the Board of Directors of AFL-ST launched a new capital increase to enable additional local governments to join the Group as shareholders.
• Since the end of the first half of the financial year, AFL has completed a new syndicated euro-denominated sustainable bond issue, maturing in 2035, for an amount of €500 million under its updated Sustainability Bond Framework. The transaction was priced at a spread of 16 basis points over the OAT curve.
• As at the date of this press release, AFL raised a total principal amount of €1,501 million on the bond markets since the beginning of 2026, at an average spread of 15 basis points over the OAT curve and completed the execution of its 2026 funding programme.

On 9 September 2026, AFL’s Executive Board formally approved AFL’s corporate and consolidated half-year financial statements for the first half of 2026. Meeting under the chairmanship of Mr. Sacha Briand on 22 September 2026, AFL’s Supervisory Board favourably reviewed AFL’s half-year financial statements.

On 22 September 2026, the Board of Directors of AFL-ST, the Société Territoriale, meeting under the chairmanship of Mrs. Marie Ducamin, approved AFL Group’s consolidated half-year financial statements.

The Statutory Auditors have completed their limited review procedures on the corporate and consolidated half-year financial statements for the period ended 30 June 2026.

This press release contains certain forward-looking statements. Although AFL Group believes that these statements are based on reasonable assumptions as of the date of publication of this press release, they are by nature subject to risks and uncertainties, including those relating to geopolitical tensions, changes in macroeconomic forecasts and developments in monetary policy, which could cause actual results to differ from those expressed or implied in such statements.

AFL Group’s financial information for the first half of 2026 consists of this press release and the report available here.   

About AFL, the public bank by and for local governments

The only French bank to be 100% owned by local governments, AFL benefits from a unique and innovative business model; that of a bank created by and for local authorities. By becoming shareholders in AFL, local authorities access quick and personalised financing for their local investments, all while signing up to a sustainable and responsible way of working. For these authorities, it provides the freedom to invest, while maintaining a well-controlled management of their finances. Since the start of its activities in 2015, AFL has already provided more than 13 billion euros in financing and now totals 1,300 shareholders.

More information: www.agence-france-locale.fr/en/ 

---

1 AFL Group comprises Agence France Locale – Société Territoriale (AFL-ST), Agence France Locale (AFL), Agence France Locale Immobilier and Agence France Locale – Participations SAS.
2 AFL’s consolidated financial statements comprise Agence France Locale, Agence France Locale Immobilier and Agence France Locale – Participations SAS.
3 Calculated by adding the Additional Tier 1 (“AT1”) interest expenses to net banking income, albeit in line with IFRS, these interest charges are directly booked as a reduction in shareholders’ equity without being recorded in the income statement.  
4 The risk weighting applicable to regions, departments, municipalities and municipality groupings with their own tax-raising powers was reduced to 0% by decision of the Supervisory College of France’s Prudential Supervision and Resolution Authority (ACPR) on 21 June 2024.

Attachments

• 2026.09.23.Press_release_AFL_2026_Half-year_results
• 2026.AFL_RAPPORT_FINAL_SEMESTRIEL_ENG_compressed
• FINAL.Rapport semestriel AFL-ST ENG S1 2026

TORONTO, Sept. 23, 2026 (GLOBE NEWSWIRE) — Osisko Gold Group Inc. (NYSE: OGG, TSXV: OGG) (“Osisko Gold” or the “Company“) announces the pricing of its offering (the “Offering“) of US$600 million aggregate principal amount of 9.250% senior secured notes due 2031 (the “Notes“) to refinance its existing senior secured project loan facility with funds advised by Appian Capital Advisory Limited (the “Appian Credit Facility“) and advance the construction of the Cariboo Gold Project in British Columbia, Canada (the “Cariboo Gold Project“), at an issue price of 100.0%. The Offering is expected to close on September 30, 2026, subject to customary closing conditions. The Offering was upsized from the previously announced offering size of US$500 million aggregate principal amount of Notes.

The Notes will pay interest semi-annually in arrears on April 1 and October 1 of each year, commencing on April 1, 2027, and will mature on October 1, 2031. The Notes will be fully and unconditionally guaranteed by certain of the Company’s subsidiaries, which, at closing, is expected to consist of Barkerville Gold Mines Ltd., the Company’s subsidiary relating to the Cariboo Gold Project, and will be secured by a first priority lien on the Company’s and each guarantor’s property, including equity interests owned by the Company and each guarantor in their respective subsidiaries, the interest reserve account and disbursement account, as described herein, and personal and real property, subject to certain exceptions.

Osisko Gold intends to use the aggregate net proceeds from the Offering, after deducting the initial purchasers’ discounts and commissions and estimated offering expenses, to

• repay all amounts outstanding, and terminate all commitments, under the Appian Credit Facility with approximately US$120.9 million of the net proceeds from this offering;
• fund a segregated interest reserve account in an amount equal to the first five interest payments on the Notes; and
• fund, with the remaining net proceeds, a segregated disbursement account with funds to be used to advance the Cariboo Gold Project.

The Notes were offered and will be sold only to persons reasonably believed to be qualified institutional buyers in accordance with Rule 144A under the United States Securities Act of 1933, as amended (the “Securities Act“), and to non-U.S. persons outside the United States pursuant to Regulation S under the Securities Act. The Notes were offered and will be sold in Canada on a private placement basis pursuant to applicable Canadian prospectus exemptions.

The offer and sale of the Notes have not been and will not be registered under the Securities Act or any state securities laws and the Notes may not be offered or sold in the United States or to U.S. persons absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws. This news release shall not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any offer or sale of the Notes in any jurisdiction in which such offer, solicitation or sale would be unlawful.

ABOUT OSISKO GOLD GROUP INC. Osisko Gold Group Inc. is a continental North American gold development company focused on past producing mining camps with district-scale potential. The Company’s objective is to become an intermediate gold producer through the development of its flagship, fully permitted, 100%-owned Cariboo Gold Project, located within the Company’s broader Cariboo regional land package in central British Columbia, Canada, which hosts numerous prospective exploration targets and provides opportunities for future discoveries. Its Cariboo project pipeline is complemented by the Tintic Project, located in the historic East Tintic mining district in Utah, U.S.A., a brownfield property with significant exploration potential, extensive historical mining data, and access to established infrastructure. Osisko Gold is focused on developing long-life mining assets in mining-friendly jurisdictions while maintaining a disciplined approach to capital allocation, development risk management, and mineral inventory growth.
Sean Roosen	Philip Rabenok
Chairman and CEO	Vice President, Investor Relations
Email: sroosen@osiskogold.ca	Email: prabenok@osiskogold.ca
Tel: +1 (514) 940-0685	Tel: +1 (437) 423-3644

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This news release contains “forward-looking information” (within the meaning of applicable Canadian securities laws) and “forward-looking statements” (within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended) (collectively, “forward-looking statements”). Such forward-looking statements, by their nature, require Osisko Gold to make certain assumptions and necessarily involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in these forward-looking statements. Such forward-looking statements are not guarantees of performance and are identified with words such as “may”, “will”, “would”, “could”, “expect”, “believe”, “plan”, “anticipate”, “intend”, “estimate”, “potential”, “propose”, “project”, “outlook”, “foresee”, “continue”, “objective”, “strategy”, variants of these words or the negative or comparable terminology, as well as terms usually used in the future and the conditional. Information contained in forward-looking statements is based upon certain material assumptions that were applied in drawing a conclusion or making a forecast or projection, including statements pertaining to: the terms of the Notes; the completion and timing of the proposed Offering; the Company’s ability to satisfy the conditions to closing of the Offering; the anticipated use of proceeds from the Offering; the ability to develop the Cariboo Gold Project and its status as being fully permitted; the Company’s objective of becoming an intermediate gold producer; and the exploration potential and potential for future discoveries (if any) of its properties; and the intention to terminate the Appian Credit Facility.

Osisko Gold considers its assumptions to be reasonable based on information currently available but cautions the reader that their assumptions regarding future events, many of which are beyond the control of Osisko Gold, may ultimately prove to be incorrect since they are subject to risks and uncertainties that affect Osisko Gold and its business. Such risks and uncertainties include, but are not limited to: the risk that the conditions to closing of the Offering are not satisfied and that the Offering is not completed; the absence of further work stoppages or suspensions at the Cariboo Gold Project; risks associated with the development and construction of the Cariboo Gold Project; risks relating to third-party approvals, including the issuance of permits by governments, favourable regulatory conditions and approvals, capital market conditions and the Company’s ability to access capital on terms acceptable to the Company for the contemplated exploration and development at the Company’s properties; the absence of unforeseen ground conditions or other geological challenges; the ability to continue current operations and exploration; regulatory framework and presence of laws and regulations that may impose restrictions on mining; errors in management’s geological modelling; the timing and ability of the Company to obtain and maintain required approvals and permits; the results of exploration activities; the availability of necessary equipment, supplies and infrastructure; risks relating to exploration, development and mining activities; the global economic climate; fluctuations in metal and commodity prices; fluctuations in the currency markets; dilution; environmental risks; and community, non-governmental and governmental actions and the impact of stakeholder actions. Readers are urged to consult the disclosure provided under the heading “Risk Factors” in the Company’s annual information form for the year ended December 31, 2025 as well as those risks and factors disclosed in the Company’s most recent financial statements and management’s discussion and analysis and other public filings filed under Osisko Gold’s issuer profile on SEDAR+ (www.sedarplus.ca) and on the SEC’s EDGAR website (www.sec.gov), for further information regarding the risks and other factors facing the Company, its business and operations. Although the Company believes the expectations conveyed by the forward-looking statements are reasonable based on information available as of the date hereof, no assurances can be given as to future results, levels of activity and achievements. The Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by law. Forward-looking statements are not guarantees of performance and there can be no assurance that these forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

Readers are cautioned that the foregoing list of assumptions, risks and uncertainties is not exhaustive. The forward-looking statements contained herein are made as of the date of this news release and, except as required by applicable law, the Company undertakes no obligation to update publicly or to revise any of the forward-looking statements, whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Experienced, Transformative Leader Tapped as Angi Transitions from Turnaround to Growth

DENVER, Sept. 22, 2026 (GLOBE NEWSWIRE) — Angi (NASDAQ: ANGI), a leading digital home services marketplace, today announced the appointment of Michael Steib as Chief Executive Officer, succeeding Jeff Kip. As CEO, Mr. Steib will remain a member of Angi’s board and lead Angi’s executive team, overseeing strategy and daily management of the company. As Mr. Steib assumes the CEO role, Joey Levin will transition from his role as Executive Chairman of the Board to Chairman. All changes are effective immediately.

Mr. Steib has extensive executive experience building category-leading digital products and durable business models at publicly traded companies, most recently as president and CEO of TEGNA (NYSE: TGNA), which was acquired by Nexstar Media Group at a substantial premium in March 2026. His track record of success for revitalizing brands and generating shareholder value extends across tech, commerce, and media, and he brings a focus on running extremely efficient and high velocity teams.  

“Mike is bringing enormous energy and spot-on experience to Angi. His palpable excitement for the brand and the product will be quickly apparent to Angi’s customers, and the opportunities Mike sees in our current AI landscape are invigorating,” said Joey Levin. “I expect Mike to continue his tremendous record of delivering meaningful incremental value for shareholders, several times over.” 

Prior to being president and CEO of TEGNA, Mr. Steib was CEO of Artsy, the leading online marketplace for buying and selling art globally. Previously, he was CEO of XO Group Inc., parent company of The Knot, where the company’s stock tripled under his leadership before it merged with WeddingWire Inc. At Artsy and XO Group, Mr. Steib was able to build industry-leading digital products and grow revenue and profitability metrics.

“Angi has an important mission, helping homeowners when they need it and delivering business to hard-working professionals,” said Michael Steib. “We’re going to use the revolutionary power of AI to make our products better for both, and we’re going to move with urgency. I see real opportunities for upsides in profitability in the near-term and I look forward to working with this team to build a bright future for Angi.”

Mr. Kip will serve as advisor to the company for six months to ensure a smooth transition. Mr. Levin expressed the Board’s appreciation for Mr. Kip’s leadership as CEO. “Jeff assumed leadership of Angi during a complex and challenging time across the shifting economic and digital landscapes. He played a pivotal role integrating multiple product and technology platforms globally, expanding margins and spurring growth. The Board thanks Jeff for his insight, unwavering dedication and foundational service to our company across multiple key roles and we wish him every success with all of his future endeavors,” Mr. Levin said.

About Angi Inc.
Angi (NASDAQ: ANGI) helps homeowners get home projects done well and helps home service professionals grow their businesses. Founded in 1995, Angi connects homeowners with skilled local professionals, from plumbers and electricians to remodelers and landscapers, and provides tools for researching costs, planning projects and hiring with confidence. Homeowners have turned to Angi, and our vast network of skilled home pros, for help with more than 300 million projects.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The use of words such as “anticipates,” “estimates,” “expects,” “plans,” “intends,” “will,” “may”, “could” and “believes,” among similar expressions, generally identify forward-looking statements. These forward-looking statements include, among others, statements relating to the leadership transition, our ability to successfully manage the leadership transition, our future business, financial condition, results of operations and financial performance, our business prospects and strategy, trends in the home services industry and other similar matters. These forward-looking statements are based on the expectations and assumptions of our management about future events as of the date of this communication, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict.

Actual results could differ materially from those contained in these forward-looking statements for a variety of reasons, including, among others: (i) the continued migration of the home services market online, (ii) our ability to market our various products and services in a successful and cost-effective manner, (iii) the continued display of links to websites offering our products and services in a prominent manner in search results, (iv) our ability to expand our pre-priced offerings while balancing the overall mix of service requests and directory services on Angi platforms, (v) our ability to establish and maintain relationships with quality and trustworthy Pros, (vi) our continued ability to develop and monetize versions of our products and services for mobile and other digital devices, (vii) our ability to access, share and use personal data about consumers, (viii) our continued ability to communicate with consumers and Pros via e-mail (or other sufficient means), (ix) our ability to continue to generate leads for Pros given changing requirements applicable to certain communications with consumers, (x) any challenge to the contractor classification or employment status of our Pros, (xi) our ability to compete, (xii) adverse economic events or trends (particularly those that impact consumer confidence and spending behavior), (xiii) our ability to maintain and/or enhance our various brands, (xiv) our ability to protect our systems, technology and infrastructure from cyberattacks and to protect personal and confidential user information (including credit card information), as well as the impact of cyberattacks experienced by third parties, (xv) the occurrence of data security breaches and/or fraud, (xvi) increased liabilities and costs related to the processing, storage, use and disclosure of personal and confidential user information, (xvii) the integrity, quality, efficiency and scalability of our systems, technology and infrastructures (and those of third parties with whom we do business), (xviii) changes in key personnel, (xix) our development and use of AI and machine learning technologies and the related legal and regulatory developments, (xx) various risks related to our relationship with IAC following the spin-off, (xxi) our ability to generate sufficient cash to service our indebtedness, (xxii) the impact of our current and future indebtedness on our ability to obtain additional financing and pursue other business opportunities and (xxiii) certain risks related to ownership of our Class A common stock.

Certain of these and other risks and uncertainties are discussed in Angi Inc.’s filings with the Securities and Exchange Commission (the “SEC”), including the most recent Annual Report on Form 10-K filed with the SEC on February 20, 2026, and subsequent reports that Angi Inc. files with the SEC. Other unknown or unpredictable factors that could also adversely affect Angi Inc.’s business, financial condition, and results of operations may arise from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those expressed in any forward-looking statements we may make. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this communication.

CONTACT: Contact Information
Angi Corporate Communications
Jennifer Myers
(303) 963-8352

Angi Investor Relations
Sophia Nam, Julie Hoarau
(720) 282-1958

CALGARY, Alberta, Sept. 22, 2026 (GLOBE NEWSWIRE) — Computer Modelling Group Ltd. (“CMG” or the “Company”) (TSX: CMG), announced today the preliminary results of its substantial issuer bid (the “SIB”), pursuant to which CMG offered to purchase for cancellation a number of its common shares (“Shares”) for an aggregate purchase price not to exceed C$20 million at a purchase price of not less than C$4.00 and not more than C$4.50 per Share. The SIB expired at 5:00 p.m. (Eastern time) on Monday, September 21, 2026.

Preliminary Results of SIB

In accordance with the terms and conditions of the SIB and based on the Company’s preliminary calculations, CMG expects to take up and pay for approximately 4,444,444 Shares at a price of C$4.50 per Share under the SIB (the “Purchase Price”), representing an aggregate purchase price of approximately C$20 million and approximately 5.7% of the total number of CMG’s issued and outstanding Shares before giving effect to the SIB and on a non-diluted basis.

Based on the preliminary calculations of Olympia Trust Company (the “Depositary”) as depositary for the SIB, approximately 4,657,844 Shares were tendered to the SIB pursuant to auction tenders and purchase price tenders, of which it is anticipated that 3,933,678 Shares (approximately 84%) will be taken up and purchased. In addition, approximately 8,966,715 Shares were tendered pursuant to proportionate tenders, of which it is anticipated that approximately 510,766 Shares will be taken up and purchased.

None of CMG’s directors or executive officers participated in the SIB. EdgePoint Investment Group Inc., which held approximately 30.8% of the Shares before giving effect to the SIB, did not tender any Shares to the SIB.

Since the SIB was oversubscribed, shareholders who made auction tenders at or below the Purchase Price and shareholders who made, or were deemed to have made, purchase price tenders will have the number of Shares purchased prorated following the determination of the final results of the SIB (other than “odd lot” tenders, which are not subject to proration). CMG currently expects that shareholders who made auction tenders at or below the Purchase Price and purchase price tenders will have approximately 84% of their successfully tendered Shares purchased by CMG.

Shareholders who made valid proportionate tenders will have such number of Shares purchased by CMG as would permit such shareholders to maintain their same Share ownership percentage as existed prior to completion of the SIB (subject to rounding to avoid the purchase of fractional Shares).

After giving effect to the SIB, CMG expects to have approximately 73.6 million Shares issued and outstanding.

The number of Shares expected to be purchased, the proration factor, the Purchase Price and the aggregate purchase price referred to above are preliminary and remain subject to verification by the Depositary. Upon take up and payment of the Shares purchased, CMG will release the final results, including the final proration factor. Payment for the Shares accepted for purchase will be made in accordance with the terms of the Offer and applicable law.

The full details of the SIB are described in the offer to purchase and issuer bid circular dated August 14, 2026, as well as the related letter of transmittal and notice of guaranteed delivery, copies of which were filed and are available under our profile on SEDAR+ at www.sedarplus.ca. CMG has engaged National Bank Financial Inc. to act as the financial advisor and dealer manager (the “Dealer Manager”) for the SIB. Any questions or requests for information regarding the SIB may be directed to the Depositary, at 1-833-684-1546 (Toll Free – North America), (587) 774-2340 or corporateactions@olympiatrust.com, or to the Dealer Manager, at 1-416-524-9514.

This press release is for informational purposes only and does not constitute an offer to buy or the solicitation of an offer to sell Shares.

Forward-Looking Information

Certain information in this press release may constitute “forward-looking information” within the meaning of applicable securities legislation. All information contained in this press release, other than statements of current and historical fact, is forward-looking information, including statements regarding the Company’s expectations with respect to the SIB, the total number of Shares to be taken up and paid for in connection with the SIB, the total number of proportionate tender shares to be taken up, the proration factor, the Purchase Price, the aggregate purchase price for all Shares taken up, the number of Shares expected to be issued and outstanding after completion of the SIB, and other statements that are not historical facts (collectively, “forward-looking information”). Generally, forward-looking information can be identified by use of words such as “may”, “will”, “expect”, “believe”, “anticipate”, “estimate”, “intend”, “plan”, “would”, “could”, “should”, “continue”, “goal”, “objective”, “remain” and other similar terminology.

Forward-looking information is not, and cannot be, a guarantee of future results or events. Forward-looking information is necessarily based on a number of opinions, estimates, and assumptions that the Company considered appropriate and reasonable as of the date such statements are made. Although the forward-looking information contained herein is based upon what the Company believes are reasonable assumptions, actual results may vary from the forward-looking information contained herein. Certain assumptions made in preparing the forward-looking information contained herein include, without limitation, that all reported tenders were validly made and the absence of changes to applicable laws, regulations or policies affecting issuer bids. Inherent in the forward-looking information are known and unknown risks, uncertainties and other factors that could cause actual results, performance or achievements, or industry results, to differ materially from any results, performance or achievements expressed or implied by such forward-looking information. Details of these risks are described in the Company’s annual publicly filed documents, including the Annual Information Form for the year ended March 31, 2026 (which are available on the Company’s profile on SEDAR+ at www.sedarplus.ca).

Investors should not place undue reliance on forward-looking information as a prediction of actual results. The forward-looking information reflects management’s current expectations and beliefs regarding future events and operating performance and is based on information currently available to management. Although we have attempted to identify important factors that could cause actual results to differ materially from the forward-looking information contained herein, there are other factors that could cause results not to be as anticipated, estimated or intended. The forward-looking information contained herein is current as of the date of this press release and, except as required under applicable law, we do not undertake to update or revise it to reflect new events or circumstances. Additionally, we undertake no obligation to comment on analyses, expectations or statements made by third parties in respect of CMG, our financial or operating results, or our securities.

About CMG

CMG (TSX: CMG) is a global software and consulting company that combines science and technology with deep industry expertise to solve complex subsurface and surface challenges for the energy industry around the world. CMG is headquartered in Calgary, AB, with offices globally. For more information, visit www.cmgl.ca.

CONTACT: For investor inquiries, please contact:

Kim MacEachern
Director, Investor Relations
cmg-investors@cmgl.ca.

For media inquiries, please contact: marketing@cmgl.ca.

JIANGYIN, China, Sept. 22, 2026 (GLOBE NEWSWIRE) — Li Bang International Corporation Inc. (“Li Bang International”) and its subsidiaries (collectively, the “Company,” “we,” “us,” “our company,” or “Li Bang”) (Nasdaq: LBGJ), a company engaged in designing, developing, producing, and selling stainless steel commercial kitchen equipment in China, today announced the results of the Company’s September 2026 Extraordinary General Meeting (the “Meeting”), as adjourned and reconvened, held at 9:30 a.m. U.S. Eastern Time on September 22, 2026. All proposals submitted for shareholder approval at the Meeting have been approved. The shareholders have duly adopted the following resolutions:

      (1)  An ordinary resolution to increase the authorized share capital of the Company from: USD $35,000 divided into 15,750,000 Class A ordinary shares with par value of USD $0.002 each share and 1,750,000 Class B ordinary shares with par value of USD $0.002 each share, to: USD $7,000,000 divided into 3,150,000,000 Class A ordinary shares with par value of USD 0.002 each share and 350,000,000 Class B ordinary shares with par value of USD $0.002 each share, by increasing the number of authorized Class A ordinary shares by 3,134,250,000, and the number of authorized Class B ordinary shares by 348,250,000 (the “Share Capital Increase”).

     (2) A special resolution, subject to and immediately following the Share Capital Increase being effected and further subject to compliance with all further applicable requirements prescribed by sections 14, 14A and 14B of the Companies Act (Revised) of the Cayman Islands (the “Companies Act”), to approve the reduction of the par value of each authorized ordinary share of the Company (including all authorized, issued and outstanding Class A ordinary shares and Class B ordinary shares) from USD $0.002 to USD $0.00001 and to authorize the board of directors of the Company (the “Board”) to take all actions necessary or advisable to effect such change (the “Share Capital Reorganization”), specifically through the following steps:

Share Capital Reduction

                    a. the par value of each issued and outstanding class A ordinary share of USD $0.002 par value each and class B ordinary share of USD $0.002 par value each in the share capital of the Company be reduced to USD $0.00001 by cancelling USD $0.00199 of the paid-up capital on each of the issued and outstanding class A ordinary shares of USD $0.002 par value each and class B ordinary shares of USD $0.002 par value each (the “Share Capital Reduction”);

                     b. following the Share Capital Reduction, the amount deemed to be paid up on each issued and outstanding share of the Company shall be USD $0.00001;

                   c. the credit arising from the Share Capital Reduction be transferred to a distributable reserve account of the Company which may be utilized by the Company as the Board may deem fit and as permitted under the Companies Act, the Company’s memorandum and articles of association, and all relevant applicable laws, including, without limitation, eliminating or setting off any accumulated losses of the Company (if any) from time to time;

Share Capital Subdivision

                        d. immediately following the Share Capital Reduction:

1. each authorized but unissued class A ordinary share of USD $0.002 par value each be subdivided into 200 class A ordinary shares of USD $0.00001 par value each; and
2. each authorized but unissued class B ordinary share of USD $0.002 par value each be subdivided into 200 Class B ordinary shares of USD $0.00001 par value each (collectively, the “Subdivision”);

Share Capital Cancellation

                        e. immediately following the Subdivision, the authorized share capital of the Company be altered by the cancellation of such number of unissued class A ordinary shares of USD $0.00001 par value each and unissued class B ordinary shares of USD $0.00001 par value each that will result in the Company having authorized share capital of USD $35,000 divided into 3,150,000,000 class A ordinary shares of par value of USD $0.00001 each and 350,000,000 class B ordinary shares of par value of USD $0.00001 each (the “Cancellation”); and

Authorized Share Capital Confirmation

                        f. immediately following the Share Capital Reduction, the Subdivision and Cancellation, the authorized share capital of the Company shall be USD $35,000 divided into 3,150,000,000 class A ordinary shares of par value of USD $0.00001 each and 350,000,000 class B ordinary shares of par value of USD $0.00001 each.

      (3) Special resolutions, subject to and immediately following the Share Capital Increase and the Share Capital Reorganization being effected, to approve the adoption by the Company of an amended and restated memorandum of association (the “New MA”), substantially in the form set forth in Exhibit A in the Explanatory Statement of the Meeting, in substitution for, and to the entire exclusion of, the Company’s currently effective amended and restated memorandum of association adopted by a special resolution passed on April 30 2026, to reflect the Share Capital Increase and the Share Capital Reorganization.

      (4)  A special resolution, subject to approval of the New MA and immediately following the completion of the filings of the New MA and further subject to all necessary governmental and regulatory consents, to approve:

1. the deregistration of the Company as an exempted company under the laws of the Cayman Islands and the continuation of the Company into the British Virgin Islands (“BVI”) as a BVI business company under the laws of BVI (the “Migration”); and
2. the adoption, conditional upon and with immediate effect from the Migration, of a memorandum and articles of association compliant with the laws of the BVI, substantially in the form attached as Exhibit B in the Explanatory Statement of the Meeting (the “BVI MAA”), in substitution and replacement in their entirety of the Company’s then existing amended and restated memorandum and articles of association.

      (5)  An ordinary resolution, subject to approval of Proposal 4 (the Migration proposal), to approve the authorization of the Board and any director or officer and of the Company to take all actions, execute all documents and make all filings as they may deem necessary or desirable to effect the Migration, including without limitation, signing (i) the voluntary declaration for and on behalf of the Company (which shall also be sworn by a Director) including a statement of the Company’s assets and liabilities as required by the Companies Act ; (ii) as the Company has no secured creditors, an undertaking that the Company has no secured creditors; (iii) a notice of the Company’s proposed registered office address in BVI, each in connection with the Company’s application to the Registrar of Companies of the Cayman Islands for the Migration, and the authorization of the Company’s registered office service providers to notify the Registrar of Companies of the Cayman Islands of the passing of the relevant special resolutions in accordance with the Companies Act.

      (6) An ordinary resolution to approve to adjourn the Meeting to a later date or dates or sine die, if necessary, to permit further solicitation and vote of proxies if, at the time of the Meeting, the Meeting becomes inquorate or there are not sufficient votes for, or otherwise in connection with, the approval of the foregoing proposals.

The approved proposals will take effect in such sequence and subject to such conditions reviewed at the Meeting and described in the Notice and Explanatory Statement of the Meeting, including any required governmental and regulatory consents and filings.

The Meeting was held originally on September 21 at 9:30 a.m. U.S. Eastern Time, and was adjourned due to the absence of a quorum and in accordance with the adjourned-meeting provisions of Article 17.7 of the Company’s currently effective amended and restated memorandum and articles of association adopted pursuant to special resolutions of the Company passed on April 30, 2026. The ordinary shares represented in person or by proxy at this adjourned Meeting, although still less than one-third (1/3) of the outstanding ordinary shares, constituted a quorum in accordance with Article 17.7 as permitted under applicable Cayman Islands law. In this respect, the Company elected to follow home country practice in the Cayman Islands in lieu of satisfying the quorum-related requirements of Nasdaq’s Listing Rule 5620(c).

About Li Bang International Corporation Inc.

Li Bang International Corporation Inc. specializes in the development, production, and sale of stainless-steel commercial kitchen equipment under its own “Li Bang” brand in China. In addition to its product offerings, the Company provides comprehensive services from early-stage design of commercial kitchen appliances to equipment installation and after-sales maintenance. Committed to innovation and high-quality, the Company uses modern production facilities and mature procedures and strives to become a first-class commercial kitchen appliance manufacturer in China. The Company’s long-term vision is to establish itself as a household name, synonymous with the products it manufactures. For more information, please visit the company’s website at https://ir.libangco.cn.

Forward Looking Statements

Certain statements in this announcement constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may”, “could”, “will”, “should”, “would”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, “project” or “continue” or the negative of these terms or other comparable terminology. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to carefully review other factors that may affect its future performance or results in the Company’s public filings with the U.S. Securities and Exchange Commission.

CONTACTS
Li Bang International Corporation Inc.
Investor Relations Department
Email: guanli@libangco.cn

WFS Investor Relations
Email: services@wfsir.com
Phone: +1 628 283 9214

SHANGHAI, Sept. 22, 2026 (GLOBE NEWSWIRE) — FREELANDER today highlighted the intelligent technology and all-terrain capability of FREELANDER 8 ahead of its Global Brand Launch at Emirates Palace Mandarin Oriental in Abu Dhabi on 29 September. As the British Premium Intelligent All-Terrain Brand prepares to introduce FREELANDER 8 to international audiences, the brand is showcasing how its technologies respond to different driving demands, from desert and gravel environments to paved roads and everyday urban mobility.

At the core of FREELANDER 8’s all-terrain performance is the Intelligent All-Terrain System (i-ATS). Featuring nine modes, the system enables the vehicle to adapt to changing surfaces and driving conditions, extending intelligent control from everyday roads to more demanding terrain.

Working alongside i-ATS, the virtual central differential lock and rear electronic limited-slip differential (e-LSD) enhance stability and traction management on challenging surfaces. Across previous product validations, FREELANDER 8 has been tested in scenarios including deserts, gravel roads, rocky terrain, steep climbs, water crossings and paved roads. Together with i-ATS, the virtual central differential lock and rear e-LSD support the vehicle’s adaptability as surfaces and driving conditions change in diverse global environments.

Beyond all-terrain driving, intelligent technology also extends to the everyday challenges of urban mobility. Super Intelligent Valet Parking (SIVP), offered in selected markets, is designed to support users across a wide range of parking scenarios, from tight urban spaces and complex surroundings to challenging weather conditions. Remote parking and vehicle summon allow users to manage parking tasks through a mobile application, while functions such as space searching and obstacle avoidance further simplify the process. Together, these features bring the principles of Smart Confidence into everyday use.

From desert terrain to urban parking, FREELANDER 8 leverages advanced technology to meet diverse demands of modern mobility. Its Intelligent All-Terrain System (i-ATS) adapts to shifting driving conditions, while SIVP delivers greater convenience for daily journeys. Blending British Craftsmanship, Smart Confidence and All-Terrain Freedom, FREELANDER 8 embodies Beyond the Legend — pairing all-terrain versatility with technology engineered for the real-world needs of Freedom Seekers.

About FREELANDER

FREELANDER is a British Premium Intelligent All-Terrain brand jointly developed by Chery and Jaguar Land Rover. JLR leads the design and premium DNA, while Chery brings advanced technology and global top-tier supply chain capabilities. The brand is supported by a strong global foundation, including over 5,000 employees, five strategic hubs, and fully integrated capabilities spanning design, R&D, manufacturing, and global operations.

Vincent CHEN
freelander.international@mychery.com
https://www.cheryinternational.com/

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/11768927-292d-4cb1-8ffa-f830a280aec5
https://www.globenewswire.com/NewsRoom/AttachmentNg/08917d9f-01b2-4f03-926a-6dbd3f3d06c0

DENVER, Sept. 22, 2026 (GLOBE NEWSWIRE) — InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE), today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock by investment funds affiliated with Apax Partners and Welsh, Carson, Anderson & Stowe (together, the “Selling Stockholders”) at a price to the public of $9.25 per share. The offering is expected to close on September 24, 2026, subject to the satisfaction of customary closing conditions. The Selling Stockholders have also granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of InnovAge’s common stock from the Selling Stockholders at the public offering price, less underwriting discounts and commissions.

InnovAge is not selling any shares of common stock in this offering and will not receive any proceeds from the sale of shares by the Selling Stockholders, but will bear the costs associated with the sale of such shares, other than any underwriting discounts and commissions.

Barclays, Goldman Sachs & Co. LLC and Wells Fargo Securities are acting as lead book-running managers and representatives of the underwriters for the proposed offering. UBS Investment Bank, William Blair and KeyBanc Capital Markets are acting as book-running managers for the proposed offering. Academy Securities and Ramirez & Co., Inc. are acting as co-managers for the proposed offering.

The Registration Statement on Form S-3 relating to these securities has been filed with the Securities and Exchange Commission (the “SEC”) and declared effective. The offering will be made only by means of a prospectus and an accompanying prospectus supplement. Before investing, prospective investors should read the prospectus, any accompanying prospectus supplement and the documents incorporated by reference therein for more complete information. A copy of the prospectus and any prospectus supplement relating to this offering may be obtained, when available, by visiting the SEC’s website at www.sec.gov. Alternatively, copies of the prospectus and prospectus supplement relating to the offering may be obtained if you request it by contacting: Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 1-888-603-5847, or by email at barclaysprospectus@broadridge.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at 866-471-2526, or by email at prospectus-ny@ny.email.gs.com; or Wells Fargo Securities, 90 South 7^th Street, 5^th Floor, Minneapolis, MN 55402, at 800-645-3751 (option #5), or email a request to WFScustomerservice@wellsfargo.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About InnovAge

InnovAge is an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE). With a mission of enabling older adults to age independently in their own homes for as long as safely possible, InnovAge’s patient-centered care model is designed to improve the quality of care participants receive while reducing over-utilization of high-cost care settings. InnovAge believes its PACE healthcare model is one in which all constituencies — participants, their families, providers and government payors — “win.” As of June 30, 2026, InnovAge served approximately 8,230 participants across 20 centers in six states.

Forward-Looking Statements – Safe Harbor

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements, including statements related to the offering and expected settlement date and about our beliefs and expectations, are based on InnovAge’s management’s beliefs, as well as assumptions made by, and information currently available to, them. Forward-looking statements can be identified by words such as: “anticipate,” “continue,” “intend,” “forward,” “focus,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and other words and terms of similar meaning that do not relate strictly to historical or current facts. Because forward-looking statements are based on expectations as to future events and are not statements of fact, actual results may differ materially from those projected. Important factors that could cause actual results to differ materially from those indicated in the forward-looking statements related to the offering include risks and uncertainties related to the satisfaction of customary closing conditions; and other risk factors identified in our SEC reports, including, our most recent Annual Report on Form 10-K and any subsequent Quarterly Report on Form 10-Q or Current Report on Form 8-K, in each case, as filed with the SEC.

The forward-looking statements in this press release are made by the Company as of the date hereof and are based on information currently available to us. Except as required by law, we undertake no obligation to publicly update any forward-looking statement, whether written or oral, whether as a result of new information, future developments or otherwise.

Investor Contact:
Ryan Kubota
RKubota@InnovAge.com

Media Contact:
press@InnovAge.com

This press release was published by a CLEAR® Verified individual.

PERTH, Australia, Sept. 22, 2026 (GLOBE NEWSWIRE) — FireFly Metals Ltd (ASX,TSX: FFM) (FireFly or the Company) is pleased to announce the release of the Technical Report required by Canadian National Instrument NI43-101 in respect of the Preliminary Economic Assessment and Mineral Resource Estimate (Technical Report) announced by the Company on 25 August 2026.

The filed Technical Report contains immaterial updates to capital expenditure for the expansion case scenario which do not impact the overall calculation of net present value (NPV) of the Green Bay Ming Mine Copper-Gold Project.

The Technical Report can be accessed on SEDAR+ at www.sedarplus.ca or on the Company’s website at https://fireflymetals.com.au/technical-reports/

This announcement has been authorised by the Board of Directors.

Contact information:

Steve Parsons Managing Director FireFly Metals Ltd +61 8 9220 9030	Jessie Liu-Ernsting Chief Development Officer FireFly Metals Ltd +1 416 572 2028	Paul Armstrong Media Contact Read Corporate +61 8 9388 1474

ABOUT FIREFLY METALS LTD

FireFly Metals Ltd (ASX, TSX: FFM) is an emerging copper-gold company focused on growing the high-grade Green Bay Copper-Gold Project in Newfoundland, Canada. The project is advancing towards development, with a Preliminary Economic Assessment showing the potential for a high-grade, low-cost and long-life operation with a pathway to produce 100kt of copper per annum.

The Green Bay Copper-Gold Project is underpinned by 60.2Mt of Measured and Indicated Mineral Resources at 2.43% for 1,464Kt copper equivalent (CuEq) and 23.5Mt of Inferred Mineral Resources at 2.51% for 592Kt CuEq, prepared and disclosed in accordance with the 2012 Edition of the Australasian Code for Reporting of Exploration Results, Mineral Resources and Ore Reserves (JORC Code (2012 Edition)) and Canadian National Instrument 43-101 – Standards of Disclosure for Mineral Projects (NI 43-101).

The Company has a clear strategy to continue growing the Green Bay Copper-Gold Project through resource expansion, new discoveries and advancement towards development.

Further information regarding FireFly Metals Ltd is available on the ASX platform (ASX: FFM), the Company’s website www.fireflymetals.com.au or SEDAR+ www.sedarplus.ca.

COMPLIANCE STATEMENTS

The Green Bay Copper-Gold Project comprises the Ming Deposit and the Little Deer Deposit.

Mineral Resource Estimate – Green Bay Copper-Gold Project

The combined Mineral Resource Estimate for the Green Bay Copper-Gold Project referred to in this announcement and set out in Appendix A was first reported in the Company’s ASX announcement dated 25 August 2026, titled ‘Green Bay Copper-Gold Project, Canada Preliminary Economic Assessment and Mineral Resource Update.’

Mineral Resource Estimate – Little Deer

The Mineral Resource Estimate for Little Deer referred to in this announcement was first reported in the Company’s ASX announcement dated 29 October 2024, titled ‘Resource Increases 42% to 1.2Mt of contained metal at 2% Copper Eq.’

Metal equivalents for Mineral Resource Estimates

Metal equivalents for the combined Green Bay Copper-Gold Project Mineral Resource Estimate have been calculated at a copper price of US$10,626/t, gold price of US$3,587/oz and silver price of US$50.22/oz.   Metal equivalents for the Little Deer Mineral Resource Estimate have been calculated at a copper price of US$8,750/t, gold price of US$2,500/oz and silver price of US$25/oz. Individual Mineral Resource grades for the metals are set out in Appendix A of this announcement.

Metallurgical factors have been applied to the metal equivalent calculation. Copper recovery used was 95%. Historical production at the Ming Mine has a documented copper recovery of ~96%. Precious metal (gold and silver) metallurgical recovery was assumed at 85% based on historical recoveries achieved at the Ming Mine in addition to historical metallurgical test work to increase precious metal recoveries.

In the opinion of the Company, all elements included in the metal equivalent calculation have a reasonable potential to be recovered and sold on the basis of current market conditions, metallurgical test work, the Company’s operational experience and, where relevant, historical performance achieved at the Green Bay project whilst in operation.

Copper equivalent for the Green Bay Copper-Gold Project was calculated based on the formula:

CuEq(%) = Cu(%) + (Au(g/t) x 0.97106) + (Ag(g/t) x 0.01360).

Copper equivalent at Little Deer was calculated based on the formula:

CuEq(%) = Cu(%) + (Au(g/t) x 0.82190) + (Ag(g/t) x 0.00822).

Original Announcements

FireFly confirms that it is not aware of any new information or data that materially affects the information included in the original announcements referred to or cross-referenced in this announcement and that, in the case of Mineral Resource Estimates, all material assumptions and technical parameters underpinning the Mineral Resource Estimates in the original announcements continue to apply and have not materially changed. The Company confirms that the form and context in which the Competent Persons’ and Qualified Persons’ findings are presented have not been materially modified from the original market announcements.

Scientific and Technical Information

Mr Juan Gutierrez, BSc, Geology (Masters), Geostatistics (Postgraduate Diploma), Group Chief Geologist at FireFly, and a Qualified Person as defined by NI 43-101, has reviewed and approved the scientific and technical disclosure contained in this announcement.

FORWARD-LOOKING INFORMATION

This announcement may contain certain forward-looking statements and projections, including statements regarding FireFly’s plans, forecasts and projections with respect to its mineral properties and programs. Forward-looking statements may be identified by the use of words such as ‘may’, ‘might’, ‘could’, ‘would’, ‘will’, ‘expect’, ‘intend’, ‘believe’, ‘forecast’, ‘milestone’, ‘objective’, ‘predict’, ‘plan’, ‘scheduled’, ‘estimate’, ‘anticipate’, ‘continue’, or other similar words and may include, without limitation, statements regarding plans, strategies and objectives.

Although the forward-looking statements contained in this announcement reflect management’s current beliefs based upon information currently available to management and based upon what management believes to be reasonable assumptions, such forward-looking statements and projections are estimates only and should not be relied upon. They are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company, which may include changes in commodity prices, foreign exchange fluctuations, economic, social and political conditions, and changes to applicable regulation, and those risks outlined in the Company’s public disclosures.

The forward-looking statements and projections are inherently uncertain and may therefore differ materially from results ultimately achieved. For example, there can be no assurance that FireFly will be able to confirm the presence of Mineral Resources or Ore Reserves, that FireFly’s plans for development of its mineral properties will proceed, that any mineralisation will prove to be economic, or that a mine will be successfully developed on any of FireFly’s mineral properties. The performance of FireFly may be influenced by a number of factors which are outside of the control of the Company, its directors, officers, employees and contractors. The Company does not make any representations and provides no warranties concerning the accuracy of any forward-looking statements or projections, and disclaims any obligation to update or revise any forward-looking statements or projections based on new information, future events or circumstances or otherwise, except to the extent required by applicable laws.

APPENDIX A

Green Bay Copper-Gold Project Mineral Resources

Ming Deposit Mineral Resource Estimate

MING DEPOSIT	TONNES	COPPER		GOLD		SILVER		CuEq
	(Mt)	Grade	Metal	Grade	Metal	Grade	Metal	Grade
		(%)	(‘000 t)	(g/t)	(‘000 oz)	(g/t)	(‘000 oz)	(%)
Measured	3.5	1.5	52	0.2	20	1.3	147	1.7
Indicated	53.8	1.9	1,041	0.5	878	4.5	7,707	2.5
TOTAL M&I	57.3	1.9	1,093	0.5	899	4.3	7,853	2.4
Inferred	17.3	2.0	344	0.7	404	6.3	3,522	2.8
LITTLE DEER	TONNES	COPPER		GOLD		SILVER		CuEq
	(Mt)	Grade	Metal	Grade	Metal	Grade	Metal	Grade
		(%)	(‘000 t)	(g/t)	(‘000 oz)	(g/t)	(‘000 oz)	(%)
Measured	–	–	–	–	–	–	–	–
Indicated	2.9	2.1	62	0.1	9	3.4	320	2.3
TOTAL M&I	2.9	2.1	62	0.1	9	3.4	320	2.3
Inferred	6.2	1.8	110	0.1	10	2.2	430	1.8
GREEN BAY TOTAL	TONNES	COPPER		GOLD		SILVER		CuEq
	(Mt)	Grade	Metal	Grade	Metal	Grade	Metal	Grade
		(%)	(‘000 t)	(g/t)	(‘000 oz)	(g/t)	(‘000 oz)	(%)
Measured	3.5	1.5	52	0.2	20	1.3	147	1.7
Indicated	56.7	1.9	1,103	0.5	887	4.4	8,027	2.5
TOTAL M&I	60.2	1.9	1,155	0.5	908	4.2	8,173	2.4
Inferred	23.5	1.9	454	0.6	414	5.2	3,952	2.5

1. FireFly Metals Ltd Mineral Resource Estimates for the Green Bay Copper-Gold Project, incorporating the Ming Deposit and Little Deer Complex, are prepared and reported in accordance with the JORC Code (2012 Edition) and NI 43-101. “M&I” means Measured and Indicated.   
2. Mineral Resources have been reported at a 1.0% copper cut-off grade.
3. Metal equivalents for the combined Green Bay Copper-Gold Project Mineral Resource Estimate have been calculated using the CIBC long term mean commodity prices as at 1 July 2026: copper price of US$10,626/t, gold price of US$3,587/oz and silver price of US$50.22/oz. Metal equivalents for the Little Deer Mineral Resource Estimate have been calculated at a copper price of US$8,750/t, gold price of US$2,500/oz and silver price of US$25/oz.   
4. Metallurgical recoveries have been set at 95% for copper and 85% for both gold and silver. These assumptions are made on the basis of historical production at the Ming Mine and additional metallurgical test work.
5. Copper equivalent for the Green Bay Copper-Gold Project was calculated based on the formula: CuEq(%) = Cu(%) + (Au(g/t) x 0.97106) + (Ag(g/t) x 0.01360). Copper equivalent at Little Deer was calculated based on the formula: CuEq(%) = Cu(%) + (Au(g/t) x 0.82190) + (Ag(g/t) x 0.00822).
6. Totals may vary due to rounding. For further details refer to the ASX announcement dated 25 August 2026, titled ‘Green Bay Copper-Gold Project, Canada Preliminary Economic Assessment and Mineral Resource Update’.